Related references
Note: Only part of the references are listed.Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
C. Craddock et al.
LEUKEMIA (2013)
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
T. Schroeder et al.
LEUKEMIA (2013)
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2012)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome
D-Y Kim et al.
BONE MARROW TRANSPLANTATION (2012)
Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity
T. Guillaume et al.
BONE MARROW TRANSPLANTATION (2012)
Azacitidine for the treatment of patients with acute myeloid leukemia
Luca Maurillo et al.
CANCER (2012)
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies
Gandhi Damaj et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U. Platzbecker et al.
LEUKEMIA (2012)
Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia
Djordje Atanackovic et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Impact of the hypomethylating agent 5-azacytidine on dendritic cells function
Jihane Frikeche et al.
EXPERIMENTAL HEMATOLOGY (2011)
Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting
Luis I. Sanchez-Abarca et al.
BLOOD (2010)
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
Jaebok Choi et al.
BLOOD (2010)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
A. Czibere et al.
BONE MARROW TRANSPLANTATION (2010)
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting
M. Luebbert et al.
BONE MARROW TRANSPLANTATION (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Low-Dose Azacitidine After Allogeneic Stem Cell Transplantation for Acute Leukemia
Elias Jabbour et al.
CANCER (2009)
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
C. Flotho et al.
LEUKEMIA (2009)
Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation
A. W. Loren et al.
BONE MARROW TRANSPLANTATION (2008)
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation
D. A. Pollyea et al.
BONE MARROW TRANSPLANTATION (2007)
Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation
Marco Mielcarek et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia
C Hosing et al.
BONE MARROW TRANSPLANTATION (2005)
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation
JE Levine et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
